Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flu-M vs Ultrix in Pregnant Women
NCT05457894Phase 3Completed
- Sponsor
- Saint Petersburg Scientific Research Institute of Vaccines and Serums
- Start
- Jan 2020
- Primary completion
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen in influenza (4 arms), sponsored by Saint Petersburg Scientific Research Institute of Vaccines and Serums. Primary endpoints: Change from Baseline Seroprotection rate at 21 days, Change from Baseline Seroconversion rate at 21 days and 1 more. Started Jan 2020; status: completed.
02
Drugs
Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05457894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05457894.